Registry for Haemorrhagic Hereditary Telangiectasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a registry for Haemorrhagic Hereditary Telangiectasia (HHT) to collect epidemiological data, risk factors, and clinical characteristics of the condition. It will involve a prospective survey to monitor diagnosis, prognosis, treatment, and survival rates among affected individuals. The registry will focus on the population served by the Hospital Italiano de Buenos Aires, providing valuable insights into the prevalence and clinical presentation of HHT in Argentina and Latin America.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with HHT defined.
2. Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

Exclusion Criteria:

1\. Denied to participated in the registry or inform consent process.

Where it's running

• Hospital Italiano de Buenos Aires
  Buenos Aires, Buenos Aires, Argentina Recruiting

Study contacts

• Principal investigator: Marcelo M Serra, MD — HHT Center of Excelence Hospital Italiano de Buenos Aires
• Study coordinator: Marcelo M Serra, MD
• Email: marcelo.serra@hospitalitaliano.org.ar
• Phone: +541149590200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immune biomarkers to predict complications after liver transplantation

  This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.

  Recruiting at 3 sites Hospital Italiano de Buenos Aires · Pilar, Buenos Aires and 2 other locations · NCT07875595

• Subanesthetic Ketamine for Depressive Symptoms in ICU Patients

  This study tests whether a short course of low-dose ketamine can help reduce depressive symptoms in adults who are in the ICU.

  Recruiting at 2 sites Phase 2 Hospital Italiano de Buenos Aires · Jacksonville, Florida and 1 other locations · NCT07639359

• Low-grade gliomas in Argentina: Incidence, survival, and treatment patterns

  This study tests how common low-grade gliomas are in Argentina and how long patients live after diagnosis, using two groups from Buenos Aires and Córdoba.

  Recruiting at 6 sites Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires F.D. and 5 other locations · NCT07631338

• Protein dose and recovery in critically ill patients with acute kidney injury

  In this study, researchers look at whether giving more than 1.2 g/kg/day of protein to ICU patients with AKI affects how quickly kidney recovery happens.

  Recruiting at 4 sites Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires and 5 other locations · NCT07631221

• Cryotherapy to Cut Opioid Use After Knee Replacement

  This trial tests whether compressive cryotherapy with a Game Ready device can lower opioid use and improve recovery after total knee replacement in adults 60–80.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT07630337

• Real-world use of a new semaglutide form (oral and injectable) for adults with type 2 diabetes in Argentina

  This study tests whether oral or injectable semaglutide helps adults with type 2 diabetes in Argentina improve HbA1c over 12 months when used in routine care.

  Recruiting at 2 sites Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires and 1 other locations · NCT07621419

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.